For radiotherapy, less can be more

See allHide authors and affiliations

Science  24 Oct 2014:
Vol. 346, Issue 6208, pp. 436-437
DOI: 10.1126/science.346.6208.436-e

Radionuclides attached to antibodies have the potential to target radiation specifically to cancer cells, reducing the damage to noncancerous cells and the side effects of radiotherapy. Clinical trials evaluating antibodies labeled with actinium-225, a radionuclide that emits high-energy α-particles, are currently under way. However, the two-step method used to label antibodies with actinium-225 is inefficient and expensive. Maguire et al. describe an improved one-step method for producing stable and therapeutically active actinium-225 antibodies. They report increases in yield and specific activity of up to 10- and 30-fold, respectively. Through lowering the cost and dose required for actinium-225 targeted therapy, this method may help to expand the clinical use of actinium-225–labeled antibodies.

J. Nucl. Med. 10.2967/jnumed.114.138347 (2014).

Stay Connected to Science

Navigate This Article